Full-Time
Phlebotomy
Versiti
1,001-5,000 employees
Blood centers providing donations and research
Compensation Overview
$28.61/hr
Crystal Lake, IL, USA
In Person
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Versiti
See people who can refer or advise you
- A high school diploma or GED is required.
- A combination of a health care degree and certification is required.
- At least 3 years of relevant experience is required.
- Typically, a minimum of 5 years of job-related experience is required.
- Demonstrate effective problem-solving and good judgment when selecting methods and techniques for obtaining solutions.
- Read and interpret Standard Operating Procedures, safety rules, operating and maintenance instructions, and other department manuals.
- Apply judgment to written or oral instructions.
- Organize work to provide productive workflow.
- Work independently and with a team.
- Maintain strong attention to detail.
- Provide constructive criticism to peers and communicate effectively.
- Learn and use computer applications including Ceridian, HemASphere, Oracle, and HemaTerra.
- Use a personal computer and general office equipment.
- Use Microsoft Suite applications including Word, Excel, PowerPoint, and Outlook.
- Use screening equipment including a lancet, sphygmomanometer, temperature probe, and hemoglobin analyzer.
- Use phlebotomy collection equipment including a blood mixer, Trima, and Alyx.
- Perform all applicable regulatory and compliance requirements.
- Lead the donor collection team, redirect issues raised by Donor Specialists, and provide feedback and follow-through with team members and supervisors.
- Provide customer-service support to donors through professional relationship building.
- Establish and build relationships with donors and sponsors.
- Resolve customer issues with potential negative impact and inform the supervisor or manager.
- Influence future blood drives through conversion rates, rebooking, sponsor leadership, and service recovery.
- Train and mentor team members in all aspects of the role.
- Prepare collection sites and perform setup, including technology systems and quality control; troubleshoot and adjust as needed; and plan future site visits.
- Perform donor screening, including collecting donor histories and conducting mini-physicals.
- Perform phlebotomy, including automation with Alyx and/or Trima.
- Prepare and pack units for transport.
- Observe donors for reactions, manage automation reactions and donor needs, de-escalate situations, prevent reactions, and mitigate situations.
- Rebook donors for future donation appointments and facilitate the rebooking process.
- Transport or carpool staff and, when needed, transport supplies and equipment.
- Operate mobile drive buses with a valid CLD while following Department of Transportation guidelines and safely transporting staff, supplies, and equipment.
- Lead drive setup.
- Create a safe environment for donors and staff and maintain team safety awareness.
- Achieve the team automation goal by recruiting and converting donors for automation.
- Operate, troubleshoot, and perform routine maintenance on equipment.
- Maintain product integrity and ensure proper identification of all donors.
- Maintain departmental records as needed.
- Participate in validation of new processes or equipment as needed.
- Review daily work for accuracy, investigate potential discrepancies and unexpected results, and resolve them where appropriate.
- Review quality results and escalate issues and concerns.
- Perform root cause analysis, review, and reporting with leadership.
- Use SOS to troubleshoot.
- Comply with all policies and standards.
- Three or more years of phlebotomy experience is preferred.
Versiti coordinates a network of linked blood centers and a research organization focused on blood health. It collects, tests, processes, stores, and distributes blood, organs, tissue, and bone marrow to hospitals to meet urgent patient needs. Its blood products and transfusion services are supported by research from the Blood Research Institute, which works on cellular therapies, oncology, and genomics to advance personalized medicine. The company differentiates itself by operating as a partnership of centers with a strong emphasis on scientific rigor, donor relationships, and broad collaboration with hospitals, aiming to be the go-to partner for blood health services. Its goal is to save lives by providing safe, available blood products while driving research to improve treatments and outcomes.
Company Size
1,001-5,000
Company Stage
Grant
Total Funding
$25.5M
Headquarters
Milwaukee, Wisconsin
Founded
2012
Get referred to Versiti
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 14, 2026 Behavioral Diagnostics expanded Versiti’s clinical-trial screening menu.
- June 8, 2026 Jorge Di Paola joined to lead VBRI and research growth.
- February 2026 secured $3 million federal funding for the Wauwatosa expansion.
What critics are saying
- August 3, 2026 donations fell 11%, causing nearly 15,000 missed appointments since Memorial Day.
- Winter cancellations already strained Michigan and Wisconsin supplies; platelet shortages recur within seven days.
- If donor attrition persists, hospitals face rationing and Versiti loses its core network advantage.
What makes Versiti unique
- Versiti combines blood collection, hospital supply, and VBRI science across five states.
- Its 2026 VBRI expansion nearly doubles research capacity and targets 50 principal scientists.
- Versiti Clinical Trial Solutions sells biomarker services to pharmaceutical sponsors, not just hospitals.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Company Match
401(k) Retirement Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Congratulations Dr. Brian Branchford! July 23, 2026 Brian Branchford, MD, receives the 2026 HTRS Mid-Career Research Award. The HTRS-funded award will support Dr. Branchford's research into platelet signaling, pediatric thromboinflammation, and safer approaches to venous thromboembolism prevention and treatment. HTRS is pleased to announce that Brian Branchford, MD, a pediatric hematologist and physician-scientist at the Versiti Blood Research Institute, has been selected as the recipient of the 2026 HTRS Mid-Career Research Award (MCRA). 2026 Award Recipient Brian Branchford, MD. Versiti Blood Research Institute 2026 HTRS Mid-Career Research Award Funded by HTRS Project Title: "Platelet-Derived Protein S Signaling Through TYRO3/MERTK in Platelet Activation and Thrombus Stability: A Pediatric Thromboinflammation Study" Advancing Pediatric Thrombosis Research. Dr. Branchford's research will advance understanding of the mechanisms underlying pediatric thromboinflammation and venous thromboembolism (VTE). His project will generate key mechanistic and translational data on platelet-derived Protein S and TYRO3/MERTK signaling. The findings are expected to support the development of safer, pediatric-specific approaches to VTE prevention and treatment while positioning the research for future NIH R01-level funding. A pediatric hematologist and physician-scientist, Dr. Branchford has dedicated his clinical and research programs to understanding and preventing venous thromboembolism in children, particularly in the setting of inflammation. His training included a pediatric residency and chief residency at Children's Hospital of Wisconsin and the Medical College of Wisconsin, followed by a fellowship in pediatric hematology, oncology, and bone marrow transplant at Children's Hospital Colorado. During his training, he gained research experience in von Willebrand factor biology, platelet biology, and murine thrombosis models. Over the past 15 years, his work has centered on thromboinflammatory platelet signaling, including the Protein S/GAS6-TAM receptor pathway, platelet activation, and thrombus stability. Leadership and collaboration. Dr. Branchford's clinical and collaborative work includes leadership in institutional thrombosis initiatives and co-founding the Children's Healthcare Advancements in Thrombosis (CHAT) Clinical Research Consortium, which studies hospital-acquired pediatric thrombosis and its risk factors. He also represents the United States on the Executive Committee of the International Pediatric Thrombosis Network (IPTN). His long-term goal is to build an independent, externally funded research program in non-malignant hematology that connects mechanistic platelet biology with pediatric thrombosis prevention. About the HTRS Mid-Career Research Award. Total Award $216,000 USD over two years Research Focus Clinical, translational, or basic science research in hemostasis and thrombosis To assist mid-career investigators in transitioning to full academic research independence and R01-equivalent funding Funding Organization Hemostasis and Thrombosis Research Society Recognizing the Awards Program Council. HTRS extends its sincere appreciation to Janice Staber, MD, Chair, and Lindsey George, MD, Vice Chair, for their leadership of the Mid-Career Research Award Committee on the HTRS Awards Program Council. Their leadership and dedication throughout the review process help ensure that HTRS continues to recognize and invest in exceptional investigators whose work advances the field of hemostasis and thrombosis. Please join HTRS in congratulating Dr. Brian Branchford on this well-deserved recognition!
Behavioral Diagnostics and Versiti Clinical Trial Solutions announce partnership to bring objective smoking and alcohol exposure screening to clinical trials. Its screenings. Have questions? Contact Us Form MILWAUKEE and CORALVILLE, Iowa (July 14, 2026) - Behavioral Diagnostics and Versiti Clinical Trial Solutions today announced a new partnership that will allow Versiti Clinical Trial Solutions to offer Behavioral Diagnostics' novel cancer risk, smoking and alcohol exposure screening assays as part of its clinical trial support services. The collaboration expands Versiti Clinical Trial Solutions' ability to help sponsors identify and monitor behavioral factors that can affect trial safety, participant retention, adherence and data interpretation. Objective assessment of smoking and alcohol exposure may help reduce protocol deviations, improve cohort selection and strengthen interpretation of study endpoints. Behavioral Diagnostics' assays use DNA methylation-based biomarkers to provide an objective, biology-based measure of risk for lung cancer, smoking intensity and heavy alcohol exposure, helping reduce reliance on self-reported information. "Clinical trials depend on clean, interpretable data," said Doug Rains, Chief Scientific Officer, Versiti Clinical Trial Solutions. "By adding Behavioral Diagnostics' screening technology to our clinical trial support capabilities, we can help sponsors better understand participant risk factors that may influence safety, adherence and study outcomes." Behavioral Diagnostics' smoking-related assay evaluates methylation at cg05575921, a biomarker associated with smoking exposure. In a study recently published in Lung Cancer, researchers reported that adding cg05575921 methylation levels to existing clinical and smoking-history variables in subjects from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial improved prediction of lung cancer occurrence in people who currently or previously smoked compared with existing gold-standard methods. In addition, the Smoke Signature CA lung cancer test provides a "hemoglobin A1c-like" assessment of smoking intensity that can be used in Precision Medicine smoking cessation therapies. The findings were especially notable among participants with less than 20 pack-year smoking histories, although the authors noted that additional validation in an external screening population is needed. The alcohol assay provides an Alcohol T Score, an objective measure associated with heavy alcohol consumption. In clinical trials, unreported or unmonitored alcohol use can introduce safety and data quality challenges, including potential drug-alcohol interactions, participant attrition, missed visits, medication nonadherence and variability that may affect efficacy and safety signals. Through the partnership, Versiti Clinical Trial Solutions may use the assays to support sponsors with: * Participant screening and eligibility decisions * Baseline risk assessment * Stratification and covariate adjustment * Longitudinal monitoring of behavioral exposure * Support for cleaner, more interpretable clinical trial datasets "Self-report has long been a limitation in assessing behavioral exposure," said Robert Philibert, MD, PhD, Chief Medical Officer and Founder, Behavioral Diagnostics. "Our assays are designed to give sponsors objective biological information that can support more informed trial design, monitoring and interpretation." The partnership reflects Versiti Clinical Trial Solutions' commitment to offering specialized laboratory and biomarker support that helps sponsors strengthen clinical trial execution while maintaining scientific and regulatory rigor.
Dayton Dragons and Versiti Blood Center to host second Blood Drive in South Dayton Toyota Diamond Club on July 15. By Dayton Dragons July 13, 2026 Dayton, Ohio - The Dayton Dragons and Versiti Blood Center are teaming up for the second of four blood drives in the new South Dayton Toyota Diamond Club on Wednesday, July 15, 2026 from 12 pm to 6 pm. Donors will get a beautiful view of the field at Day Dayton, Ohio - The Dayton Dragons and Versiti Blood Center are teaming up for the second of four blood drives in the new South Dayton Toyota Diamond Club on Wednesday, July 15, 2026 from 12 pm to 6 pm. Donors will get a beautiful view of the field at Day Air Ballpark in the heart of the Water Street District and once donations are complete will get a special behind-the-scenes tour concluding in a photo on the field. Donors who "step up to the plate" will also receive a Dragons prize pack valued at $50. The prize pack includes two (2) tickets to an upcoming Dragons game, a 25th Season Commemorative poster, and a Dragons hat. Donors during the July 15 blood drive, will also receive a Versiti Blood Center water bottle while supplies last. Versiti Blood Center will also be adding a ballpark staple, hot dogs, to their post-donation recovery snacks while supplies last. Appointments are encouraged. Book your appointment for the blood drive in the South Dayton Toyota Diamond Club Event through the Versiti Blood Center website, donate.versiti.org, or by phone at (937) 461-3220. Free parking for the Blood Drive will be available at the following locations: * On the plaza at Day Air Ballpark * Metered spots near Dragons Box Office on Monument Avenue * Marsh & McLennan Parking Lot (309 Webster Street, Dayton, OH 45402) * Good Neighbor House (627 E 1st St, Dayton, OH 45402) Paid parking lots and metered spots are also available around the ballpark near the South Dayton Toyota Diamond Club. Blood donations are essential year-round, with local hospitals relying on volunteer donors to meet ongoing patient needs, including trauma care, surgeries, cancer treatments, and chronic illnesses. The Dragons and Versiti Blood Center have teamed up for the next three years to make blood donations easier and more rewarding than ever for the Miami Valley community to get involved. Blood donation requirements: Donors are required to provide a photo ID that includes their full name. Past Community Blood Center donors are also asked to bring their CBC donor ID card. Donors must be at least 17 years of age (16 years old with parental consent: form available at www.givingblood.org or at CBC branch & blood drive locations), weigh a minimum of 110 pounds (you may have to weigh more, depending on your height), and be in good physical health. About Versiti Blood Center of Ohio: Versiti Blood Center of Ohio is a nonprofit organization dedicated to providing a safe and stable blood supply to hospitals across the region while advancing patient care through research, innovation, and community engagement. To learn more or to schedule a donation, visit versitidayton.org.
Hendricks County Bank and Trust to host Versiti Blood drive during the Brownsburg 4th of July Parade. June 22, 2026 (Brownsburg, IN) - Hendricks County Bank and Trust Company (HCBT) is proud to partner with Versiti Blood Center of Indiana to host a community blood drive on Saturday, July 4. The Versiti blood mobile will be at the HCBT headquarters, located at 1 E. Main St., Brownsburg, IN 46112. The Versiti blood mobile will be available from 8 a.m. to noon, in conjunction with activities for the Brownsburg Lions Club 4th of July Parade, giving parade attendees, community members and local families a convenient opportunity to donate blood while celebrating Independence Day in downtown Brownsburg. The Brownsburg Lions Club 4th of July Parade is scheduled for 10 a.m. on July 4. The parade is one of the largest in Hendricks County and features local organizations, first responders, businesses, clubs and community groups. As America celebrates 250 years of freedom, HCBT invites the community to give one powerful gift- the gift of life. "At HCBT, our mission is rooted in improving quality of life in the communities we serve. We are honored to use this opportunity to support a lifesaving cause," said Jerry Orem, President of HCBT. "Partnering on a blood drive during such a visible community event is another way we can help connect people with opportunities to make a difference close to home." Versiti Blood Center of Indiana provides blood products and services to hospitals across the state and regularly hosts community blood drives at schools, workplaces and local events. Blood donations help support patients facing surgery, trauma care, cancer treatments and other urgent medical needs. Versiti supplies blood to over 90 hospitals in Indiana and, locally, is the sole supplier of blood products to Hendricks Regional Hospital. Community members are encouraged to sign up here to help secure a donation time in advance. Walk-ins will be welcome as availability allows. Donors should bring a photo ID and allow about one hour for the donation process. Versiti also recommends eating a healthy meal and drinking plenty of water before donating. As a thank you, all attempting donors with a valid e-mail will receive a $25 e-gift card from Versiti! "We focus on a neighbor-supporting-neighbor mission to ensure that when blood is needed, it is available in our local hospitals. You never know who will need blood next," said Hannah Akers of Versiti. The mission statement of Hendricks County Bank and Trust is to promote economic prosperity - improving the quality of life in the community Wyrz serve. Founded in 1908, Hendricks County Bank and Trust Company has been locally operated for 118 years. With five locations in the county, Hendricks County Bank provides outstanding customer service along with the latest technology and innovative products. The bank's employees from the President and Board Members to the customer service representatives are engaged in Hendricks County so they understand the local economy and the areas that are served. Visit the bank's website at HCBT.bank for more details.
Versiti: Jorge Di Paola, MD, to lead Versiti Blood Research Institute as executive vice president and chief scientific officer. MILWAUKEE - (June 8, 2026) - Versiti announced today that after an extensive national search, Jorge Di Paola, MD, an internationally recognized physician-scientist, hematology researcher and academic leader, has been appointed executive vice president and chief scientific officer for Versiti. Effective October 1st, he will direct the globally recognized Versiti Blood Research Institute (VBRI), lead as a member of Versiti's executive team, and serve as both Associate Dean of Research and Professor of Pediatrics at Medical College of Wisconsin. Di Paola currently serves as professor of pediatrics and molecular genetics and genomics at Washington University School of Medicine in St. Louis, where he is division chief of pediatric hematology and oncology and holder of the Elizabeth Finney McDonnell Endowed Chair in Pediatric Hematology Oncology. His research has helped advance understanding of inherited bleeding disorders, platelet biology, genomics, and blood diseases, and he has authored more than 200 scientific publications. A longtime collaborator with Versiti investigators, Di Paola has worked alongside VBRI researchers for more than two decades, including scientific collaborations connected to the landmark NIH-funded Zimmerman Program focused on von Willebrand disease and blood disorders research. Since 2018, he has served as an adjunct investigator at the VBRI. "Jorge is a deeply respected scientist, physician and leader whose work has helped shape the field of hematology and blood research," said Chris Miskel, president and CEO of Versiti. "What makes this especially meaningful for Versiti is that Jorge already knows our mission, our people and the scientific culture that defines the VBRI. He understands how discovery, clinical care and partnership come together to improve lives. We are grateful that he will help lead the next chapter of research and innovation at Versiti." Di Paola's scientific and leadership accomplishments span research, clinical medicine, mentorship, and national scientific leadership. He currently serves as deputy editor of Blood, one of the field's leading peer-reviewed journals, and previously served as president of the American Society of Pediatric Hematology/Oncology. He also has held leadership roles with the International Society on Thrombosis and Haemostasis, as well as on multiple National Institutes of Health programs and study sections. In addition to his scientific contributions, Di Paola is widely recognized for building and mentoring physician-scientist training programs and expanding translational research initiatives. At Washington University School of Medicine, he helped lead significant growth in pediatric hematology-oncology research, clinical trials, and faculty recruitment. "Versiti has been an important part of my scientific career for many years," Di Paola said. "I have had the opportunity to collaborate with extraordinary investigators across the VBRI and witness firsthand the institute's growth, scientific rigor, and commitment to advancing blood health. This is a remarkable moment for blood research and translational medicine, and I believe Versiti is uniquely positioned to help shape the future of the field through discovery, innovation, and collaboration." The VBRI is internationally recognized for discoveries and advances in transfusion medicine, blood disorders, genomics, transplantation, cellular therapies, and related fields. Di Paola will lead the institute's scientific strategy and research growth efforts while helping strengthen collaborations across academic medicine, healthcare, and biomedical research. About Versiti Versiti is a national leader in blood health innovation, formed with the mission to improve the health of patients and enable the success of healthcare partners nationwide. Versiti provides innovative solutions in transfusion medicine, transplantation, and blood-related diseases to meet the needs of each customer. Together, these efforts support improved patient outcomes, expanded access to care and greater efficiency for healthcare systems. For more information, visit Versiti.org.